SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 ...

A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...

CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational ...

Skin cancer is a common type of cancer that can occur anywhere on the body Read to find out about the least expected areas ...

Bicara Therapeutics (BCAX) announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in ...

Symptoms often include a painless neck lump and a sore throat. The main risk factors for tonsil cancer are smoking, drinking alcohol and infection with the human papilloma virus (HPV). Most tonsil ...

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have received a consensus rating of “Buy” from the thirteen ratings firms that are covering the firm, MarketBeat reports. One analyst ...

Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the company, Ratings reports. Three ...

The Andaman cobra is one of the rarest and least known of all cobra species. It is endemic to the Andaman and Little Andaman ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...